People: Osiris Therapeutics Inc (OSIR.OQ)

OSIR.OQ on NASDAQ Stock Exchange Global Market

22 Jul 2014
Price Change (% chg)

$-0.01 (-0.07%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Debrabandere, Lode 

Brief Biography

Dr. Lode Debrabandere, Ph.D., is President, Chief Executive Officer, Director of Osiris Therapeutics, Inc. Dr. Debrabandere has over 20 years of experience leading R&D, sales and marketing activities in the pharmaceutical and biotechnology industries. In 2006, he joined Osiris as Vice President and General Manager of the Therapeutics Business Unit and was responsible for the development of Prochymal(R) (remestemcel-L), the world's first approved stem cell drug for graft versus host disease. In 2012, he was promoted to Chief Operating Officer and assumed responsibility for all commercial activities of the company. Prior to joining Osiris, Dr. Debrabandere served as Vice President of Global Marketing at Bristol Myers Squibb where he led the Neuroscience Business Unit and was the Global Brand Leader for Abilify(TM). He joined BMS from UCB Pharmaceuticals, Inc., where he led the Clinical Development and Marketing Operations focusing on the areas of allergy/respiratory (Zyrtec(TM)) and neurology (Keppra(TM)).

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
366,750 -- 140,000 506,750

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 37,500 211,798.00
Search Stocks